Drug profile · INN
insulin glargine-aldy
LANGLARA
insulin glargine-aldy (LANGLARA) is an FDA-listed pharmaceutical active ingredient. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — insulin glargine-aldy
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 20
- Programs
- 1
- Data quality
- 0.89
Quick answer
insulin glargine-aldy (LANGLARA) is an FDA-listed pharmaceutical active ingredient. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
-
US 12428389
Diarylamide compound and application thereof
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted -
US 12194065
Methods and compositions to enhance metabolic detoxification systems
granted -
US 12171761
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 12128044
Fused tricyclic compounds and uses thereof in medicine
granted -
US 11679143
FGF21 variant, fusion protein and application thereof
granted -
US 11517569
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 11447498
Fused tetracyclic compounds and uses thereof in medicine
granted -
US 11396495
Amine compound for inhibiting SSAO/VAP-1 and use thereof
granted -
US 11285153
Substituted pyrimidine piperazine compound and use thereof
granted -
US 11261190
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 11242335
Fluorine-substituted indazole compounds and uses thereof
granted -
US 11142527
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 11122832
Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise
granted -
US 10966970
Fused tricyclic compounds and uses thereof in medicine
granted -
US 10927089
Diaryl thioether piperazine compounds, preparation methods and uses thereof
granted -
US 10751339
Substituted aminopyrimidine compounds and methods of use
granted -
US 10688090
Vilazodone inclusion complexes, compositions and preparation thereof
granted -
US 10316025
Substituted piperazine compounds and methods of use and use thereof
granted -
US 10266521
Substituted heteroaryl compounds and methods of use
granted
Frequently asked questions
What is insulin glargine-aldy?
insulin glargine-aldy (LANGLARA) is an FDA-listed pharmaceutical active ingredient. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin glargine-aldy?
LANGLARA is a marketed brand name for insulin glargine-aldy. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin glargine-aldy?
insulin glargine-aldy has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.